Entellus Medical (ENTL) Earning Somewhat Favorable Press Coverage, Report Shows

News headlines about Entellus Medical (NASDAQ:ENTL) have been trending somewhat positive on Monday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Entellus Medical earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 45.7634127231872 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Entellus Medical (NASDAQ ENTL) traded down $0.02 during midday trading on Monday, reaching $24.04. The company’s stock had a trading volume of 56,200 shares, compared to its average volume of 202,577. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $25.58. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. The stock has a market cap of $616.58, a PE ratio of -18.64 and a beta of 0.02.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Wednesday, November 1st. The medical technology company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.02. Entellus Medical had a negative return on equity of 47.37% and a negative net margin of 31.24%. equities analysts forecast that Entellus Medical will post -1.33 EPS for the current year.

Several equities research analysts recently weighed in on the company. BidaskClub cut Entellus Medical from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Canaccord Genuity reiterated a “hold” rating and issued a $17.00 price objective on shares of Entellus Medical in a report on Tuesday, October 17th. TheStreet upgraded Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. Finally, ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $19.25.

In other news, insider Robert S. White sold 3,471 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $24.01, for a total value of $83,338.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brian E. Farley sold 101,319 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $23.85, for a total value of $2,416,458.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,942 shares of company stock valued at $2,599,658. Company insiders own 7.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2018/01/22/entellus-medical-entl-earning-somewhat-favorable-press-coverage-report-shows.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply